Dupilumab (Dupixent®)

Selected References:

- Akhtar NH et. al. 2022. The use of dupilumab in severe atopic dermatitis during pregnancy: a case report. Allergy Asthma Clin Immunol. 18(1):9.
- Avallone G, et al. 2024. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 6(1)1-10.
- Bosma AL, et al. 2021. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. Clin Exp Dermatol. 46(6):1089-1092.
- Center for Drug Evaluation and Research (CDER). Dupilumab pharmacology review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761055Orig1s000PharmR.pdf. Accessed 23 June 2026.
- Chan T, et al, 2020. Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update. J Formos Med Assoc. 120(1:Pt2):429-442.
- Chopra CR, et al. 2025. Maternal, Fetal, and Labour Outcomes of Dupilumab Use for Atopic Dermatitis During Pregnancy: A Systematic Review. J Cutan Med Surg. 29(1):51-55.
- Costley M, Murphy B. 2022. Severe atopic dermatitis treated successfully with dupilumab throughout pregnancy. 2022. Clin Exp Dermatol 47(5):960-961.
- Di Lernia V, Peccerillo F, 2024. Long-Term Follow-Up of Dupilumab Treatment During Conception, Pregnancy and Lactation. Indian J Dermatol. 69(2):193-195.
- Escolà H, et al. 2023. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients. J Eur Acad Dermatol Venereol. 37(9)p.e1156-e1160.
- Gracia-Darder I, et al. 2022). Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy. Dermatol Ther. 35(2) e15247.
- Hong N, et al. 2024. Atopic dermatitis treated safely with dupilumab during pregnancy and lactation: A case series of four patients. Australas J Dermatol. 00:1-4.
- Heilskov S, et al. 2020. Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature. Dermatol Ther (Heidelb) 10(6): 1215–1228.
- Jang W, et al. 2025. Use of Biologics to Treat Asthma during Pregnancy and Adverse Events in Pregnant Women and Newborns: A Global Pharmacovigilance Analysis. Int Arch Allergy Immunol. 186(9):875-888.
- Kage P, et al. 2020. A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. Journal of the European Academy of Dermatology and Venereology: JEADV, 34(6), e256–e257.
- Kage P, et al. 2021. Case of atopic eczema treated with dupilumab throughout conception, pregnancy, and lactation. J Dermatol 48(10):E484-E485.
- Khamisy-Farah R, et al. 2021. Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™) Eur Rev Med Pharmacol Sci. 25(17):5448-5451.
- Lobo Y, et al. 2021. Atopic Dermatitis Treated Safety with Dupilumab during Pregnancy: A Case Report and Review of the Literature. Case Rep Dermatol. 13:248–256.
- Metko, D. et al. 2024. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities. JAAD Int. 15:5-11.
- Mian M, et al. 2020. Dupilumab for the treatment of severe atopic dermatitis in a pregnant patient: A case report. JAAD Case Reports. 6(10), 1051–1052.
- Napolitano M, et al. 2021. New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding. Dermatol Ther. 34:e14475.
- Preuß S, et al. 2025. Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A

propensity-matched cohort study. J Eur Acad Dermatol Venereol. 39(9):1576-1587.

- Riquelme-Mc Loughlin C, Mascaró JM Jr. 2021. Treatment of pemphigoid gestationis with dupilumab. Clin Exp Dermatol. 46(8):1578-1579.
- Sánchez-García V, et al 2025. Safety of dupilumab therapy for atopic dermatitis during pregnancy: A systematic review and meta-analysis. Acta Derm Venereol.105:adv41307.
- Sanofi-Aventis U.S. Dupixent® Prescribing Information. Available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?. Accessed on 23 June 2026.
- Vestergaard C, et al. 2019. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 33(9):1644-1659.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Dupilumab (Dupixent®)

Selected References:

- Barrau M, et al. 2023. What should we know about drug levels and therapeutic drug monitoring during pregnancy and breastfeeding in inflammatory bowel disease under biologic therapy? J Clin Med; 12(23):7495.
- Bell C, et al. 2021. Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. J Gastroenterol Hepatol; 36(10):2640-2648.
- Caballero-Mateos AM, et al. 2023. IBD and motherhood: A journey through conception, pregnancy and beyond. J Clin Med; 12(19):6192.
- Chambers CD, et al. 2026. Birth outcomes in women who have taken vedolizumab in pregnancy: Results from the vedolizumab pregnancy exposure registry. Am J Gastroenterol; 1;121(3):720-732.
- Chugh R. 2023. Maternal and neonatal outcomes in vedolizumab and ustekinumab exposed pregnancies: Results from the PIANO registry. Am J Gastroenterol; 1;119(3):468-476.

- Ding N, et al. 2022. Management of biologics in pregnant, lactating patients with inflammatory bowel disease and the impact on neonatal vaccination: A systematic review of clinical practice guidelines and consensus statements. J Clin Pharm Ther; 47(12):1952-1965.
- Ernest-Suarez K, et al. 2025. Live rotavirus vaccination appears low-risk in infants born to mothers with inflammatory bowel disease on biologics. Clin Gastroenterol Hepatol; 23(5):835-845.
- Gisbert JP, et al. 2023. Vaccines in children exposed to biological agents in utero and/or during breastfeeding: Are they effective and safe? J Crohns Colitis; 17 (6):995-1009.
- Gisbert JP, et al. 2020. Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: A review. Drugs; 80(11):1085-1100.
- Honap S, et al. 2023. An update on the safety of long-term vedolizumab use in inflammatory bowel disease. Expert Opin Drug Saf; 22 (9):767-776.
- Julsgaard M, et al. 2017. Vedolizumab safety in pregnancy and newborn outcomes. Gut; 66(10):1866-1867.
- Julsgaard M, et al. 2018. Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease. Gastroenterology; 154: 752-765.
- Lahat A, et al. 2018. Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis; 12:120-3.
- Lamb CA, et al. 2019. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut; 68(Suppl 3):s1-s106.
- Laube R, et al. 2021. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf; 20(3):275-292.
- Mahadevan U, et al. 2017. Vedolizumab exposure in pregnancy: Outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther; 45:941-950.
- Mahadevan U, et al. 2017. Editorial: vedolizumab in pregnancy – is gut selectivity as good for baby as it is for mum? Authors' reply. Aliment Pharmacol Ther; 45(9):1284.
- Meyer A, et al. 2025. Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease. Clin Gastroenterol Hepatol; 23(1):144-153.e22.
- Mitrova K, et al. 2022. Safety of ustekinumab and vedolizumab during pregnancy-Pregnancy, neonatal, and infant outcome: A prospective multicentre study. J Crohn's Colitis; 16(12):1808-1815.
- Moens A, et al. 2019. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. J Crohns Colitis; 13(1):12-13.
- Moens A, et al. 2020. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther; 51(1):129-138.
- Nguyen B, et al. 2026. Safety of vedolizumab in pregnancy: An updated systematic review and comprehensive meta-analysis. Journal of Clinical Gastroenterology; 60(3):225-231.
- Nielsen OH. 2022. Biologics for inflammatory bowel disease and their safety in pregnancy: A systematic review and meta-analysis. Clin Gastroenterol Hepatol; 20(1):74-87.
- Pingeon O, et al. 2026. Safety of advanced therapies during pregnancy in women with immune-mediated inflammatory diseases: a systematic review and meta-analysis. J Crohns Colitis; 8;20(5):jjag045.
- Prentice R, et al. 2025. Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Clin Gastroenterol Hepatol; 23(1):124-133.e7.
- Pugliese D, et al. 2024. New drugs for the treatment of IBD during conception, pregnancy, and lactation. Dig Liver Dis; 56(2):235-241.
- Rosario M, et al. 2017. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet; 56(11): 1287–1301.
- Sheridan J, et al. 2017. Letter: Vedolizumab in Pregnancy. J Crohns Colitis; 11(8):1025-1026.
- Shitrit AB-G A, et al. 2019. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: A first perspective comparison study. Am J Gastroenterol; 114(7): 1172-1175.
- Sun W, et al. 2021. Vedolizumab concentrations in breast milk: Results from a prospective, postmarketing, milk-

only lactation study in nursing mothers with inflammatory bowel disease. Clin Pharmacokinet; 60:811-8.
- Takeda Pharmaceuticals America, Inc. 2026. Entyvio product label. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Dupilumab (Dupixent®)

Selected References:

- Ahn KH, et al. 2015. Pregnancy outcomes with paternal exposure to finasteride, a synthetic 5-alpha-reductase inhibitor: a case-series. J Clin Toxicol. 5:2
- AlSaad D, et al. 2018. Finasteride use during pregnancy and early neonatal outcome: a case report. Int J Clin Pharm. 40(4): 803-805.
- Amory JK, et al. 2007. The effect of 5- alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 92:1659-1665.
- Anderson CA, Clark RL. 1990. External genitalia of the rat: normal development and the histogenesis of 5 alpha-reductase inhibitor-induced abnormalities. Teratology. 42:483-496.
- Bowman CJ, et al. 2003. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 74:393-406.
- Carlin JR, et al. 1992. Disposition and pharmacokinetics of (14C) finasteride after oral administration in humans. Drug Metab Dispos. 20(2):148-155.
- Cather JC, et al. 1999. Finasteride – An update and review. Cutis. 64:167-172.
- Ciotta L, et al. 1995. Clinical and endocrine effects of finasteride, a 5(alpha)-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril. 64:299-306.
- Clark RL, et al: Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5(alpha)-reductase inhibitor. Toxicol Appl Pharmacol. 119:34-40.

- Clark RL, et al. 1990. External genital abnormalities in male rats exposed in utero to finasteride, a 5-alpha reductase inhibitor. Teratology. 42:91-100.
- Falsetti L, et al. 1997. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. Gynecol Endocrinol. 11(4):251-257.
- Husmann DA, McPhaul MJ. 1991. Time-specific androgen blockade with flutamide inhibits testicular descent in the rat. Endocrinology. 129(3):1409-1416.
- Gupta AK, Talukder M. 2022. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? J Cosmet Dermatol. 21(5), 1841-1848.
- Khera M, et al. 2020. Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia. Transl Androl Urol. 9(3): 1201-1209.
- Kohler C, et al. 2007. Effect of finasteride 5mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 23:142-145.
- Kurzrock EA, et al. 2000. Urethral development in the fetal rabbit and induction of hypospadias: a model for human development. J Urol. 164(5):1786-1792.
- Laborde E, Brannigan RE. 2010. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. J Androl. 31(2): e1-2.
- Lumachi F, Rondinone R. 2003. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril. 79(4):942-946.
- Martinez AG, et al. 2011. Effects of in utero exposure to D-004, a lipid extract from Roystonea regia fruits, in the male rat: a comparison with finasteride. J Med Food. 14(12):1663-1669.
- Nabil I, et al. 2024. Protective role of hesperidin in finasteride-induced testicular toxicity in adult male Wistar rats: Insights into oxidative stress, apoptosis, and ultrastructure of seminiferous tubules. Reprod Toxicol.124:108535.
- Overstreet JW, et al. 1999. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol. 162:1295-1300.
- Paris JJ, et al. 2011. Inhibition of 5 alpha reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progestogen milieu of juvenile rat offspring. J Neuroendocrinol. 23(11):1079-1090.
- Prahalada S, et al. 1997. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the Rhesus monkey (Macaca mulatta). Teratology. 55(2):119-131.
- Propecia prescribing information. 2020. Accessible from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e07adb4-7807-47d3-b9a9-2332a3047410#S12.3 Accessed June 2026.
- Ricci G, et al. 2012. Finasteride and fertility: case report and review of the literature. J Drugs Dermatol. 11(12):1511-1513.
- Rittmaster, RS, 1994. Drug Therapy: Finasteride. New Engl J Med 330(2):120-125.
- Salvarci A, Istanbulluoglu O. 2013. Secondary infertility due to use of low-dose finasteride. Int Urol Nephrol. 45(1):83-85.
- Samplaski MK, et al. 2013. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 100:1528-1529.
- Santana FFV, et al. 2023. Comparative effects of finasteride and minoxidil on the male reproductive organs: A systematic review of in vitro and in vivo evidence. Toxicol Appl Pharmacol. 478:116710.
- Spencer JR, et al. 1991. Effects of flutamide and finasteride on rat testicular descent. Endocrinology. 129(2):741-748.
- Teichert M, et al. 2017. Contraindicated use of 5-alpha-reductase inhibitors in women. Br J Clin Pharmacol. 83(2): 429-431
- Wise LD, et al. 1991. Reversible decreases of fertility in male Sprague-Dawley rats treated orally with finasteride, a 5-alpha-reductase inhibitor. Reprod Toxicol. 5:353-362.
- Zeng Y, et al. 2025. Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis

based on the FDA adverse event reporting system. Andrology. 13(6):1420-1431.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Dupilumab (Dupixent®)

Selected References:

- Ajiji P, et al. 2021. Investigating the efficacy and safety of metronidazole during pregnancy; A systematic review and meta-analysis. Eur J Obstet Gynecol Repr Biol; X,11,100128.
- Boissiere-O'Neill T, et al. 2026. Exposure to Systemic Antimicrobials During Pregnancy and Risk of Miscarriage: A Population-Based Registry Study. BJOG; 133(7):1394-1404.
- Burtin P, et al. 1995. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol; 172(21):525-529.
- Cantu JM, Garcia-Cruz D. 1982. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects Orig Artic Ser; 18(3 Pt A):85-88.
- Caro-Paton T, et al. 1997. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol; 44:(2)179-182.
- Cram LF, et al. 2015. Genitourinary infections and their association with preterm labor. Am Fam Physician; 65(2), 241–248.
- Czeizel AE, Rockenbauer M. 1998. A population-based case-control teratologic study of oral metronidazole. Br J Obstet Gynaecol; 105(3):322-327.
- Diav-Citrin O, et al. 2001. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology; 63(5):186-192.
- Einarson A, et al. 2000. Can we use metronidazole during pregnancy and breastfeeding? Putting an end to the controversy. Can Fam Physician; 46:1053-1054.
- Finegold SM. 1980. Metronidazole. Ann Intern Med; 93:585-587.
- Flagyl® Prescribing Information. Available online

at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020334s015lbl.pdf. Accessed June 2025.

- Gilbert NM, et al. 2013. Urinary tract infection as a preventable cause of pregnancy complications: Opportunities, challenges, and a global call to action. Glob Adv Health Med; 2(5):59–69.
- Gray MS, et al. 1961. Further observations on metronidazole (Flagyl). Br J Vener Dis; 37:278-279.
- Heisterberg L, Branebjerg PE. 1983. Blood and milk concentrations of metronidazole in mothers and infants. J Perinat Med; 11:114-120.
- Kazy Z, et al. 2005. Teratogenic potential of vaginal metronidazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol; 123(2):174-178.
- Koss CA, et al. 2012. Investigation of Metronidazole Use during Pregnancy and Adverse Birth Outcomes. Antimicrob Agents Chemother; 56(9): 4800-4805.
- Löfmark S, et al. 2010. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis; 50(S1):S16–S23.
- Muanda FT, et al. 2017. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ; 189(17):E625-E633.
- Nwosu OC, Bloom K. The safety of metronidazole in pregnancy. Health Care Women Int; 2021;42(4-6):726-738.
- Omranipoor A et al. 2020. Association of antibiotics therapy during pregnancy with spontaneous miscarriage: a systematic review and meta-analysis. Arch Gynecol Obstet; 302(1): 5-22.
- Passmore CM, et al. 1988. Metronidazole excretion in human breastmilk and its effect on suckling neonates. Br J Clin Pharmacol; 26(1):45-51.
- Piper JM, et al. 1993. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol; 82(3):348-352.
- Rosa FW, et al. 1987. Pregnancy outcomes after first trimester vaginitis drug therapy. Obstet Gynecol; 69(5):751-755.
- Sheehy O, et al. 2015. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf; 10(2):170-179.
- Workowski KA, Bolan GA. 2015. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep; 64:1-137.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Dupilumab (Dupixent®)

Selected References:

- Ahuja S, Gharde PM. 2023. A narrative review of maternal and perinatal outcomes of dengue in pregnancy. Cureus; 15(11): e48640.
- Arragain L, et al. 2017. Vertical transmission of dengue virus in the peripartum period and viral kinetics in newborns and breast milk: new data. J Pediatric Infect Dis Soc; 6:324-331.
- Barkham TM, et al. 2006. The performance of RT-PCR compared with a rapid serological assay for acute dengue fever in a diagnostic laboratory. Trans R Soc Trop Med Hyg; 100:142-148.
- Basurko C, et al. 2018. A prospective matched study on symptomatic dengue in pregnancy. PloS One; 13:e0202005.
- Basurko C, et al. 2018. Estimating the risk of vertical transmission of dengue: a prospective study. Am J Trop Med Hyg; 98(6): 1826-1832.
- Brar R, et al. 2021. Maternal and fetal outcomes of dengue fever in pregnancy: a large prospective and descriptive observational study. Arch Gynecol Obstet; 304:91–100.
- Centers for Disease Control and Prevention. 2025. About a Dengue Vaccine. Accessed June 2026 from https://www.cdc.gov/dengue/vaccine/index.html.
- Centers for Disease Control and Prevention. 2026. Areas with Risk of Dengue. Accessed June 2026 from https://www.cdc.gov/dengue/areas-with-risk/index.html.
- Centers for Disease Control and Prevention. 2025. Dengue. Accessed June 2026 from https://www.cdc.gov/dengue/about/index.html.
- Centers for Disease Control and Prevention. 2025. Clinical Testing Guidance for Dengue. Accessed June 2026 from https://www.cdc.gov/dengue/hcp/diagnosis-testing/index.html.
- Centers for Disease Control and Prevention. 2025. Dengue Vaccination: What Everyone Should Know. Accessed June 2026 from https://www.cdc.gov/vaccines/vpd/dengue/public/index.html.
- Centers for Disease Control and Prevention. 2025. How Dengue Spreads. Accessed June 2026 from https://www.cdc.gov/dengue/transmission/index.html.
- Centers for Disease Control and Prevention. 2025. Preventing Dengue. Accessed June 2026 from https://www.cdc.gov/dengue/prevention/index.html.
- Centers for Disease Control and Prevention. 2024. Preventing Mosquito Bites. Accessed June 2026 from https://www.cdc.gov/mosquitoes/prevention/index.html.
- Centers for Disease Control and Prevention. Your Infant has Dengue. Accessed June 2026 from https://www.cdc.gov/dengue/media/pdfs/protect-your-baby.pdf.
- Centers for Disease Control and Prevention. N.d. https://www.cdc.gov/dengue/training/cme/ccm/page45893.html#:~:text=Lifelong%20type%2Dspecific%20immunity.,about%202%20to%206%20months.
- Cerqueira-Silva T, et al. 2025. Perinatal outcomes of symptomatic chikungunya, dengue and Zika infection during pregnancy in Brazil: a registry-based cohort study. Nat Commun; 16(1):7207.
- Charlier C, et al. 2017. Arboviruses and pregnancy: maternal, fetal, and neonatal effects. Lancet Child Adolesc Health; 1:134–146.
- Chigateri S, et al. 2025. Dengue haemorrhagic fever (DHF) in pregnancy. BMJ Case Rep; 18(3):e263274.
- Garavito-Pérez PA, et al. 2025. Fatal Outcome in a Pregnant Woman with HELLP Syndrome and Dengue. Am J Trop Med Hyg; 113(2):344-346.

- Goicochea-Ríos EDS, et al. 2025. Dengue infection during pregnancy and the occurrence of pathological neonatal outcome: a systematic review and meta-analysis. F1000Res; 13:1523.
- Hcini N, et al. 2024. Arboviruses and pregnancy: are the threats visible or hidden?. Tropical diseases, travel medicine and vaccines; 10(1), 4.
- Iannetta M, et al. 2017. Persistent detection of dengue virus in vaginal secretions of a woman returning from Srin Lanka to Italy. Euro Surveill; 22(34).
- Lalle E, et al. 2018. Prolonged detection of dengue virus RNA in the semen of a man returning from Thailand to Italy. Euro Surveill; 23(18).
- Lee C, Lee H. 2018. Probable female to male sexual transmission of dengue virus infection. Infect Dis (Lond):1-3.
- Mons J, et al. 2022. Effects of Acute Dengue Infection on Sperm and Virus Clearance in Body Fluids of Men. Emerging infectious diseases; 28(6), 1146–1153.
- Nascimento LB, et al. 2017. Symptomatic dengue infection during pregnancy and livebirth outcomes in Brazil, 2007–13: a retrospective observational cohort study. Lancet Infect Dis; 17:949–956.
- Paixão ES, et al. 2016. Dengue during pregnancy and adverse fetal outcomes: a systematic review and meta-analysis. Lancet Infect Dis; 16:857–865.
- Paixão ES, et al. 2018. Symptomatic dengue during pregnancy and congenital neurologic malformations. Emerg Infect Dis; 24:1748–1750.
- Pouliot SH, et al. 2010. Maternal dengue and pregnancy outcomes: a systematic review. Obstet Gynecol Surv; 65(2):107-118.
- Pourzangiabadi M, et al. 2025. Dengue virus: etiology, epidemiology, pathobiology, and developments in diagnosis and control – a comprehensive review. Infect Genet Evol; 127:105710.
- Rathore SS, et al. 2022. Maternal and foetal-neonatal outcomes of dengue virus infection during pregnancy, Trop. Med. Int. Health: 27(7):619–629.
- Ribero CF, et al. 2016. Dengue during pregnancy: Association with Low Birth Weight and Prematurity. Rev Inst Med Trop Sao Paulo; 58:8.
- Shabil M, et al. 2024. Dengue infection during pregnancy and adverse birth outcomes: a systematic review and meta-analysis. Rev Med Virol; 34(5):e2582.
- Sinha R, Datta MR. 2023. Dengue in Early Pregnancy: A Neglected Problem?. Cureus; 15(5):e38740.
- Smith A, et al. 2024. Exposure to dengue virus during pregnancy: incidence and impact on maternal and child outcomes. Am J Trop Med Hyg; 112(2):396-402.
- Sondo KA, et al. 2019. Dengue infection during pregnancy in Burkina Faso: a cross-sectional study. BMC Infect Dis; 19:997.
- Tan PC, et al. 2008. Dengue infection in pregnancy: prevalence, vertical transmission, and pregnancy outcome, Obstet. Gynecol; 111(5):1111–1117.
- U E, Sivakumar T, et al. 2025. A Systematic Review and Meta-Analysis of Maternal Dengue Infection and Adverse Pregnancy Outcomes. Cureus; 17(11):e96888.
- Vélez Jaramillo Y, et al. 2025. Maternal and foetal outcomes in women with gestational Dengue: A systematic review. Infez Med; 33(1):15-28.
- World Health Organization. 2024. Dengue and severe dengue. Retrieved May 2024 from https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
- Xiong YQ, et al. 2017. Dengue virus infection during pregnancy increased the risk of adverse fetal outcomes? An updated meta-analysis. J Clin Virol; 94:42.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.